Global Blood Therapeutics, Inc.
GBT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $194,749 | $123,803 | $2,108 | $0 |
| % Growth | 57.3% | 5,773% | – | – |
| Cost of Goods Sold | $3,316 | $1,986 | $48 | $0 |
| Gross Profit | $191,433 | $121,817 | $2,060 | $0 |
| % Margin | 98.3% | 98.4% | 97.7% | – |
| R&D Expenses | $212,135 | $155,122 | $174,556 | $131,307 |
| G&A Expenses | $0 | $0 | $117,088 | $51,435 |
| SG&A Expenses | $266,988 | $210,851 | $117,088 | $51,435 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $479,123 | $365,973 | $291,644 | $182,742 |
| Operating Income | -$287,147 | -$243,172 | -$281,283 | -$182,742 |
| % Margin | -147.4% | -196.4% | -13,343.6% | – |
| Other Income/Exp. Net | -$15,467 | -$4,381 | $14,517 | $8,549 |
| Pre-Tax Income | -$302,614 | -$247,553 | -$266,766 | -$174,193 |
| Tax Expense | $477 | $0 | $0 | $0 |
| Net Income | -$303,091 | -$247,553 | -$266,766 | -$174,193 |
| % Margin | -155.6% | -200% | -12,654.9% | – |
| EPS | -4.82 | -4.04 | -4.57 | -3.41 |
| % Growth | -19.3% | 11.6% | -34% | – |
| EPS Diluted | -4.82 | -4.04 | -4.57 | -3.41 |
| Weighted Avg Shares Out | 62,925 | 61,334 | 58,322 | 51,151 |
| Weighted Avg Shares Out Dil | 62,925 | 61,334 | 58,322 | 51,151 |
| Supplemental Information | – | – | – | – |
| Interest Income | $720 | $5,834 | $0 | $0 |
| Interest Expense | $15,467 | $9,809 | $0 | $0 |
| Depreciation & Amortization | $8,616 | $10,823 | $9,932 | $4,607 |
| EBITDA | -$278,531 | -$226,921 | -$256,834 | -$169,586 |
| % Margin | -143% | -183.3% | -12,183.8% | – |